Tumor-infiltrating lymphocytes: their phenotype, functions and clinical use.
作者信息
Whiteside T L, Parmiani G
机构信息
Pittsburgh Cancer Institute Immunologic Monitoring and Diagnostic Laboratory, University of Pittsburgh School of Medicine, Pa. 15213-2582.
出版信息
Cancer Immunol Immunother. 1994 Jul;39(1):15-21. doi: 10.1007/BF01517175.
Abstract
摘要
相似文献
1
Tumor-infiltrating lymphocytes: their phenotype, functions and clinical use.
Cancer Immunol Immunother. 1994 Jul;39(1):15-21. doi: 10.1007/BF01517175.
2
[Tumor-infiltrating lymphocytes (TIL)].
Pol Arch Med Wewn. 1995 Jul;94(1):76-83.
3
[The antitumor effects of tumor-infiltrating lymphocytes (TIL) being proliferated in vitro].
Zhonghua Bing Li Xue Za Zhi. 1992 Apr;21(2):79-81.
4
Tracking the elusive lymphocyte: methods of detection during adoptive immunotherapy.
Immunol Invest. 2007;36(5-6):807-27. doi: 10.1080/08820130701712867.
5
Genetically modified tumor-infiltrating lymphocytes for cancer therapy.
Cancer Cells. 1991 Jul;3(7):271-4.
6
Adoptive cellular immunotherapy for cancer: interleukin-2 activated lymphocytes.
Curr Opin Oncol. 1989 Dec;1(2):249-57.
7
The Factors Affecting Expansion of Reactive Tumor Infiltrating Lymphocytes (TIL) From Bladder Cancer and Potential Therapeutic Applications.
Front Immunol. 2021 Feb 25;12:628063. doi: 10.3389/fimmu.2021.628063. eCollection 2021.
8
[Isolation and expansion of glioma-infiltrating lymphocytes in vitro: an analysis of their surface phenotypes and antitumor activities].
Hokkaido Igaku Zasshi. 1991 Nov;66(6):868-78.
9
Mechanisms of adoptive immunotherapy: improved methods for in vivo tracking of tumor-infiltrating lymphocytes and lymphokine-activated killer cells.
Cancer Res. 1993 May 15;53(10 Suppl):2358-67.
10
Functional and phenotypic analyses of interleukin 2-activated tumor-infiltrating lymphocytes.
Biotherapy. 1990;2(3):247-59. doi: 10.1007/BF02173526.
引用本文的文献
1
Minimal PD-1 expression in mouse and human NK cells under diverse conditions.
J Clin Invest. 2020 Jun 1;130(6):3051-3068. doi: 10.1172/JCI133353.
2
Characterizing the Dysfunctional NK Cell: Assessing the Clinical Relevance of Exhaustion, Anergy, and Senescence.
Front Cell Infect Microbiol. 2020 Feb 13;10:49. doi: 10.3389/fcimb.2020.00049. eCollection 2020.
3
Uterine Leiomyoma with Massive Lymphoid Infiltrate in a Patient with History of Assisted In-Vitro Fertilization.
Turk Patoloji Derg. 2020;36(3):251-255. doi: 10.5146/tjpath.2019.01476.
4
VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors.
J Exp Med. 2015 Feb 9;212(2):139-48. doi: 10.1084/jem.20140559. Epub 2015 Jan 19.
5
Head and neck squamous carcinomas with exophytic and endophytic type of growth have the same prognosis after surgery and adjuvant radiotherapy.
Eur Arch Otorhinolaryngol. 2013 Mar;270(3):1105-14. doi: 10.1007/s00405-012-2117-1. Epub 2012 Aug 4.
6
Cutting edge: delay and reversal of T cell tolerance by intratumoral injection of antigen-loaded dendritic cells in an autochthonous tumor model.
J Immunol. 2010 Jun 1;184(11):5954-8. doi: 10.4049/jimmunol.1000265. Epub 2010 Apr 28.
7
A Combination of Systemic and Intracranial Anti-CD25 Immunotherapy Elicits a Long-Time Survival in Murine Model of Glioma.
J Oncol. 2009;2009:963037. doi: 10.1155/2009/963037. Epub 2010 Mar 21.
8
Progress and challenges in the vaccine-based treatment of head and neck cancers.
J Exp Clin Cancer Res. 2009 May 27;28(1):69. doi: 10.1186/1756-9966-28-69.
9
Rapid tolerization of virus-activated tumor-specific CD8+ T cells in prostate tumors of TRAMP mice.
Proc Natl Acad Sci U S A. 2008 Sep 2;105(35):13003-8. doi: 10.1073/pnas.0805599105. Epub 2008 Aug 22.
10
Signaling defects in anti-tumor T cells.
Immunol Rev. 2008 Apr;222:192-205. doi: 10.1111/j.1600-065X.2008.00606.x.
本文引用的文献
1
Usage of T-cell receptor V beta chain genes in fresh and cultured tumor-infiltrating lymphocytes from human melanoma.
Int J Cancer. 1993 May 28;54(3):383-90. doi: 10.1002/ijc.2910540306.
2
Tumor antigens recognized by cytolytic T lymphocytes: present perspectives for specific immunotherapy.
Int J Cancer. 1993 May 8;54(2):177-80. doi: 10.1002/ijc.2910540202.
3
High efficiency gene transfer into primary human tumor explants without cell selection.
Cancer Res. 1993 May 15;53(10 Suppl):2221-6.
4
Adoptive immunotherapy of advanced melanoma patients with interleukin-2 (IL-2) and tumor-infiltrating lymphocytes selected in vitro with low doses of IL-2.
Cancer Immunol Immunother. 1993 May;36(5):315-22. doi: 10.1007/BF01741170.
5
T cell recognition of human tumors: implications for molecular immunotherapy of cancer.
Clin Immunol Immunopathol. 1993 Feb;66(2):91-106. doi: 10.1006/clin.1993.1012.
6
Analysis of T cell receptor variability in tumor-infiltrating lymphocytes from a human regressive melanoma. Evidence for in situ T cell clonal expansion.
J Clin Invest. 1993 Mar;91(3):1183-90. doi: 10.1172/JCI116278.
7
8
Tumor-infiltrating lymphocytes from ovarian tumors of low malignant potential.
Int J Gynecol Pathol. 1993 Jan;12(1):41-50. doi: 10.1097/00004347-199301000-00006.
9
10
T cell receptor (TCR) structure of autologous melanoma-reactive cytotoxic T lymphocyte (CTL) clones: tumor-infiltrating lymphocytes overexpress in vivo the TCR beta chain sequence used by an HLA-A2-restricted and melanocyte-lineage-specific CTL clone.
J Exp Med. 1993 Oct 1;178(4):1231-46. doi: 10.1084/jem.178.4.1231.
Zotero 插件